SAB Biotherapeutics, Inc. SABS
3.07 USD -0.03 (-0.97%)
At closeNov 11, 2026, 4:48 AM EST
3.37 +0.30 +9.77%
Pre-market · Nov 11, 4:48 AM ET
2.96 Day range 3.14
2.44 52-week range 5.15
- YTD
- -17.91%
- 1 year
- -4.06%
News
marketbeat.com What SAB Biotherapeutics (SABS) Said on Its Q3 Earnings Call SAB Biotherapeutics NASDAQ: SABS reaffirmed its timeline for completing enrollment in its pivotal Type 1 diabetes study by the end of 2026, as the company reported a wider research spending bill and…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock increased by 17.5% to $0.06 during Friday's after-market session. The company's market cap stands at $1.3 million. Nkarta (NASDAQ:NKTX) stock…
seekingalpha.com SAB Biotherapeutics, Inc. (SABS) Q3 2026 Earnings Call Transcript SAB Biotherapeutics, Inc. (SABS) Q3 2026 Earnings Call Transcript
benzinga.com SAB Biotherapeutics Q3 2026 Earnings Call Transcript SAB Biotherapeutics (NASDAQ:SABS) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
globenewswire.com SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights Adult and adolescent cohorts fully enrolled in registrational SAFEGUARD study of SAB-142; Pediatric cohort (ages 5–11) actively enrolling with overall enrollment on track for completion in Q4 2026
benzinga.com FDA Provides Fast Track Designation SAB Biotherapeutics' SAB-142 To Treat Stage 3 Type 1 Diabetes SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune…